<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001428'>Somatic mutation</z:hpo> of the N-ras oncogene occurs frequently in de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>By virtue of their relation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) provide an in vivo model of human <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>By using a strategy for analysis of gene mutation based on in vitro amplification of target sequences by the polymerase chain reaction (PCR) and selective oligonucleotide hybridization we analyzed the mutational status of codons 12, 13, and 61 of Ha-ras, K-ras, and N-ras in peripheral blood (PB) and/or bone marrow (BM) in 34 cases of primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Mutations at codon 12 of Ki-ras or N-ras were detected in three cases (9%): one of six cases of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) and two of nine cases of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>The nucleotide substitution differed in each </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> cases the mutant allele was detectable in PB cells </plain></SENT>
<SENT sid="6" pm="."><plain>A sustained hematologic remission was achieved after low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> therapy in the case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Neither case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> exhibited signs of disease progression during follow-up at 7 and 12 months </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, four of 31 patients without the ras mutation underwent transformation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> within 12 months of genetic analysis </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that ras mutations in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> and may develop at an early stage during the evolution of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Their detection in PB cells illustrates the potential utility of ras mutation as a clonal marker in <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancy</z:e> </plain></SENT>
</text></document>